Innoviva (FRA:HVE) Cyclically Adjusted Revenue per Share: €3.27 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HVE Innoviva Inc FRA:HVE
86 GF Score
Price €18.20
GF Value €17.79
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Innoviva Cyclically Adjusted Revenue per Share?

Innoviva FRA:HVE -2.67% 86 Cyclically Adjusted Revenue per Share is €3.27 as of Mar. 2026. GuruFocus rates FRA:HVE with a GF Score™ of 86/100 and a GF Value™ of €17.79 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Innoviva's adjusted revenue per share for the three months ended in Mar. 2026 was €0.999. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €3.27 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Innoviva's average Cyclically Adjusted Revenue Growth Rate was 15.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 20.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 24.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 29.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Innoviva was 35.50% per year. The lowest was 7.20% per year. And the median was 30.55% per year.

As of today (2026-08-01), Innoviva's current stock price is €18.20. Innoviva's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €3.27. Innoviva's Cyclically Adjusted PS Ratio of today is 5.57.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Innoviva was 37.35. The lowest was 4.85. And the median was 10.33.


Innoviva  (FRA:HVE) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Innoviva's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=18.20/3.27
=5.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Innoviva was 37.35. The lowest was 4.85. And the median was 10.33.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Innoviva Cyclically Adjusted Revenue per Share Related Terms


Innoviva Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Innoviva's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innoviva Cyclically Adjusted Revenue per Share Chart

Innoviva Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 1.47 2.32 2.98 3.03

Innoviva Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.03 2.88 3.02 3.03 3.27

FRA:HVE vs TSHA, MLTX, RXRX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Innoviva's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoviva Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoviva's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Innoviva's Cyclically Adjusted PS Ratio falls into.


FRA:HVE
86GF Score
Innoviva Inc FRA:HVE
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innoviva Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Innoviva's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.999/330.2130*330.2130
=0.999

Current CPI (Mar. 2026) = 330.2130.

Innoviva Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.232 241.018 0.318
201609 0.243 241.428 0.332
201612 0.261 241.432 0.357
201703 0.315 243.801 0.427
201706 0.433 244.955 0.584
201709 0.341 246.819 0.456
201712 0.493 246.524 0.660
201803 0.374 249.554 0.495
201806 0.506 251.989 0.663
201809 0.466 252.439 0.610
201812 0.620 251.233 0.815
201903 0.431 254.202 0.560
201906 0.500 256.143 0.645
201909 0.526 256.759 0.676
201912 0.603 256.974 0.775
202003 0.627 258.115 0.802
202006 0.617 257.797 0.790
202009 0.663 260.280 0.841
202012 0.655 260.474 0.830
202103 0.632 264.877 0.788
202106 0.831 271.696 1.010
202109 1.018 274.310 1.225
202112 1.167 278.802 1.382
202203 0.872 287.504 1.002
202206 1.070 296.311 1.192
202209 0.709 296.808 0.789
202212 0.649 296.797 0.722
202303 0.794 301.836 0.869
202306 1.142 305.109 1.236
202309 0.731 307.789 0.784
202312 0.926 306.746 0.997
202403 0.843 312.332 0.891
202406 1.484 314.175 1.560
202409 1.281 315.301 1.342
202412 0.814 315.605 0.852
202503 1.307 319.799 1.350
202506 1.030 322.561 1.054
202509 1.081 324.800 1.099
202512 1.147 324.054 1.169
202603 0.999 330.213 0.999

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €3.27 mean?
Innoviva (FRA:HVE) has a Cyclically Adjusted Revenue per Share of €3.27 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Innoviva and its competitors.
Is Innoviva's Cyclically Adjusted Revenue per Share too high?
Innoviva's current Cyclically Adjusted Revenue per Share is €3.27. Overall, Innoviva has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innoviva's Cyclically Adjusted Revenue per Share compare to TSHA and MLTX?
Innoviva's Cyclically Adjusted Revenue per Share of €3.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Innoviva and its competitors. Innoviva's current Cyclically Adjusted Revenue per Share is €3.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innoviva stock overvalued right now?
Based on GuruFocus' analysis, Innoviva (FRA:HVE) is currently considered Fairly Valued. The stock's GF Value™ is €17.79, compared to a current price of €18.20 — trading 2.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €3.27. Innoviva's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Innoviva (FRA:HVE), the current Cyclically Adjusted Revenue per Share is €3.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innoviva (FRA:HVE) Overvalued in 2026?

Based on GuruFocus' analysis, Innoviva stock appears to be overvalued. The current stock price of €18.20 is trading 2.3% above its estimated GF Value™ of €17.79. GuruFocus considers Innoviva to be Fairly Valued.

Key valuation signals for FRA:HVE:

  • Cyclically Adjusted Revenue per Share: €3.27
  • GF Value™: €17.79 vs. price of €18.20 (2.3% above fair value)
  • GF Score™: 86/100 with 3 warning signs

No single metric tells the full story. See the FRA:HVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Innoviva Business Description

Other Exchanges INVA:USA
Address 1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
86GF Score

Get the complete analysis for FRA:HVE

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.20
Price
€17.79
GF Value